Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 16

1.

Functional Comparison of Blood-Stage Plasmodium falciparum Malaria Vaccine Candidate Antigens.

Illingworth JJ, Alanine DG, Brown R, Marshall JM, Bartlett HE, Silk SE, Labbé GM, Quinkert D, Cho JS, Wendler JP, Pattinson DJ, Barfod L, Douglas AD, Shea MW, Wright KE, de Cassan SC, Higgins MK, Draper SJ.

Front Immunol. 2019 Jun 4;10:1254. doi: 10.3389/fimmu.2019.01254. eCollection 2019.

2.

Assessment of novel vaccination regimens using viral vectored liver stage malaria vaccines encoding ME-TRAP.

Bliss CM, Bowyer G, Anagnostou NA, Havelock T, Snudden CM, Davies H, de Cassan SC, Grobbelaar A, Lawrie AM, Venkatraman N, Poulton ID, Roberts R, Mange PB, Choudhary P, Faust SN, Colloca S, Gilbert SC, Nicosia A, Hill AVS, Ewer KJ.

Sci Rep. 2018 Feb 21;8(1):3390. doi: 10.1038/s41598-018-21630-4.

3.

Human vaccination against Plasmodium vivax Duffy-binding protein induces strain-transcending antibodies.

Payne RO, Silk SE, Elias SC, Milne KH, Rawlinson TA, Llewellyn D, Shakri AR, Jin J, Labbé GM, Edwards NJ, Poulton ID, Roberts R, Farid R, Jørgensen T, Alanine DG, de Cassan SC, Higgins MK, Otto TD, McCarthy JS, de Jongh WA, Nicosia A, Moyle S, Hill AV, Berrie E, Chitnis CE, Lawrie AM, Draper SJ.

JCI Insight. 2017 Jun 15;2(12). pii: 93683. doi: 10.1172/jci.insight.93683. eCollection 2017 Jun 15.

4.

Germinal Center B Cell and T Follicular Helper Cell Responses to Viral Vector and Protein-in-Adjuvant Vaccines.

Wang C, Hart M, Chui C, Ajuogu A, Brian IJ, de Cassan SC, Borrow P, Draper SJ, Douglas AD.

J Immunol. 2016 Aug 15;197(4):1242-51. doi: 10.4049/jimmunol.1502472. Epub 2016 Jul 13.

5.

Preclinical Assessment of Viral Vectored and Protein Vaccines Targeting the Duffy-Binding Protein Region II of Plasmodium Vivax.

de Cassan SC, Shakri AR, Llewellyn D, Elias SC, Cho JS, Goodman AL, Jin J, Douglas AD, Suwanarusk R, Nosten FH, Rénia L, Russell B, Chitnis CE, Draper SJ.

Front Immunol. 2015 Jul 8;6:348. doi: 10.3389/fimmu.2015.00348. eCollection 2015.

6.

Assessment of humoral immune responses to blood-stage malaria antigens following ChAd63-MVA immunization, controlled human malaria infection and natural exposure.

Biswas S, Choudhary P, Elias SC, Miura K, Milne KH, de Cassan SC, Collins KA, Halstead FD, Bliss CM, Ewer KJ, Osier FH, Hodgson SH, Duncan CJ, O'Hara GA, Long CA, Hill AV, Draper SJ.

PLoS One. 2014 Sep 25;9(9):e107903. doi: 10.1371/journal.pone.0107903. eCollection 2014.

7.

Combining viral vectored and protein-in-adjuvant vaccines against the blood-stage malaria antigen AMA1: report on a phase 1a clinical trial.

Hodgson SH, Choudhary P, Elias SC, Milne KH, Rampling TW, Biswas S, Poulton ID, Miura K, Douglas AD, Alanine DG, Illingworth JJ, de Cassan SC, Zhu D, Nicosia A, Long CA, Moyle S, Berrie E, Lawrie AM, Wu Y, Ellis RD, Hill AV, Draper SJ.

Mol Ther. 2014 Dec;22(12):2142-54. doi: 10.1038/mt.2014.157. Epub 2014 Aug 26.

8.

Analysis of human B-cell responses following ChAd63-MVA MSP1 and AMA1 immunization and controlled malaria infection.

Elias SC, Choudhary P, de Cassan SC, Biswas S, Collins KA, Halstead FD, Bliss CM, Ewer KJ, Hodgson SH, Duncan CJ, Hill AV, Draper SJ.

Immunology. 2014 Apr;141(4):628-44. doi: 10.1111/imm.12226.

9.

Assessment of antibody-dependent respiratory burst activity from mouse neutrophils on Plasmodium yoelii malaria challenge outcome.

Llewellyn D, de Cassan SC, Williams AR, Douglas AD, Forbes EK, Adame-Gallegos JR, Shi J, Pleass RJ, Draper SJ.

J Leukoc Biol. 2014 Feb;95(2):369-82. doi: 10.1189/jlb.0513274. Epub 2013 Oct 25.

10.

The utility of Plasmodium berghei as a rodent model for anti-merozoite malaria vaccine assessment.

Goodman AL, Forbes EK, Williams AR, Douglas AD, de Cassan SC, Bauza K, Biswas S, Dicks MD, Llewellyn D, Moore AC, Janse CJ, Franke-Fayard BM, Gilbert SC, Hill AV, Pleass RJ, Draper SJ.

Sci Rep. 2013;3:1706. doi: 10.1038/srep01706.

11.

Recent advances in antibody-inducing poxviral and adenoviral vectored vaccine delivery platforms for difficult disease targets.

de Cassan SC, Draper SJ.

Expert Rev Vaccines. 2013 Apr;12(4):365-78. doi: 10.1586/erv.13.11. Review.

PMID:
23560918
12.

T cell responses induced by adenoviral vectored vaccines can be adjuvanted by fusion of antigen to the oligomerization domain of C4b-binding protein.

Forbes EK, de Cassan SC, Llewellyn D, Biswas S, Goodman AL, Cottingham MG, Long CA, Pleass RJ, Hill AV, Hill F, Draper SJ.

PLoS One. 2012;7(9):e44943. doi: 10.1371/journal.pone.0044943. Epub 2012 Sep 12.

13.

The requirement for potent adjuvants to enhance the immunogenicity and protective efficacy of protein vaccines can be overcome by prior immunization with a recombinant adenovirus.

de Cassan SC, Forbes EK, Douglas AD, Milicic A, Singh B, Gupta P, Chauhan VS, Chitnis CE, Gilbert SC, Hill AV, Draper SJ.

J Immunol. 2011 Sep 1;187(5):2602-16. doi: 10.4049/jimmunol.1101004. Epub 2011 Aug 3.

14.

Enhancing blood-stage malaria subunit vaccine immunogenicity in rhesus macaques by combining adenovirus, poxvirus, and protein-in-adjuvant vaccines.

Draper SJ, Biswas S, Spencer AJ, Remarque EJ, Capone S, Naddeo M, Dicks MD, Faber BW, de Cassan SC, Folgori A, Nicosia A, Gilbert SC, Hill AV.

J Immunol. 2010 Dec 15;185(12):7583-95. doi: 10.4049/jimmunol.1001760. Epub 2010 Nov 22.

15.

Tailoring subunit vaccine immunogenicity: maximizing antibody and T cell responses by using combinations of adenovirus, poxvirus and protein-adjuvant vaccines against Plasmodium falciparum MSP1.

Douglas AD, de Cassan SC, Dicks MD, Gilbert SC, Hill AV, Draper SJ.

Vaccine. 2010 Oct 18;28(44):7167-78. doi: 10.1016/j.vaccine.2010.08.068.

16.

Investigating the induction of vaccine-induced Th17 and regulatory T cells in healthy, Mycobacterium bovis BCG-immunized adults vaccinated with a new tuberculosis vaccine, MVA85A.

de Cassan SC, Pathan AA, Sander CR, Minassian A, Rowland R, Hill AV, McShane H, Fletcher HA.

Clin Vaccine Immunol. 2010 Jul;17(7):1066-73. doi: 10.1128/CVI.00047-10. Epub 2010 May 19. Erratum in: Clin Vaccine Immunol. 2011 Apr;18(4):696.

Supplemental Content

Loading ...
Support Center